Dendritic cell-based immunotherapy in mesothelioma

Immunotherapy

Volumn 4, Issue 10, 2012, Pages 1011-1022

  Cornelissen, Robin ^a   Lievense, Lysanne A ^a   Heuvers, Marlies E ^a   Maat, Alexander P ^a   Hendriks, Rudi W ^a   Hoogsteden, Henk C ^a   Hegmans, Joost P ^a   Aerts, Joachim G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

dendritic cell; immature dendritic cell; immunotherapy; mesothelioma; myeloid derived suppressor cell; regulatory T cell; tumor associated macrophage

Indexed keywords

ALPHA2A INTERFERON; AMATUXIMAB; ANTINEOPLASTIC AGENT; ASBESTOS; BCG VACCINE; BEVACIZUMAB; CAT 5001; CISPLATIN; DENDRITIC CELL VACCINE; ERLOTINIB; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; MITOMYCIN; PEMETREXED; RALTITREXED; REACTIVE OXYGEN METABOLITE; THALIDOMIDE; UNCLASSIFIED DRUG; VINDESINE; VORINOSTAT;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR IMMUNITY; DENDRITIC CELL; DNA DAMAGE; DRUG ERUPTION; DRUG FEVER; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MESOTHELIOMA; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA;

EID: 84869177688     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.108     Document Type: Review

References (125)

1. Cooke WE. Fibrosis of the lungs due to the inhalation of asbestos dust. Br. Med. J. 2(3317), 147-140.2 (1924).
2. Cooke WE. Asbestos dust and the curious bodies found in pulmonary asbestosis. Br. Med. J. 2(3586), 578-580 (1929).
3. Seiler HE. A case of pneumoconiosis: Result of the inhalation of asbestos dust. Br. Med. J. 2(3543), 982-991 (1928).
4. Doll R. Mortality from lung cancer in asbestos workers. Br. J. Ind. Med. 12(2), 81-86 (1955).
5. Rombola G. Asbestos and pulmonary carcinoma in an asbestos worker; problems of carcinogenic action of asbestos. Med. Lav. 46(4), 242-250 (1955).
6. Klemperer P, Rabin C. Primary neoplasms of the pleura. A report of five cases. Arch. Pathol. 11, 385-412 (1931).
7. Eisenstadt HB, Wilson FW. Primary malignant mesothelioma of the pleura. J. Lancet 80, 511-514 (1960).
8. Davis JM. The histopathology and ultrastructure of pleural mesotheliomas produced in the rat by injections of crocidolite asbestos. Br. J. Exp. Pathol. 60(6), 642-652 (1979).
9. Moalli PA, MacDonald JL, Goodglick LA, Kane AB. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am. J. Pathol. 128(3), 426-445 (1987).
10. Shin ML, Firminger HI. Acute and chronic effects of intraperitoneal injection of two types of asbestos in rats with a study of the histopathogenesis and ultrastructure of resulting mesotheliomas. Am. J. Pathol. 70(3), 291-313 (1973).
11. Wagner JC, Berry G. Mesotheliomas in rats following inoculation with asbestos. Br. J. Cancer 23(3), 567-581 (1969).
12. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am. J. Respir. Crit. Care Med. 157(5 Pt 1), 1666-1680 (1998).
13. Hansen K, Mossman BT. Generation of superoxide (O2-.) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res. 47(6), 1681-1686 (1987).
14. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320(5876), 674-677 (2008).
15. Tanaka S, Choe N, Hemenway DR, Zhu S, Matalon S, Kagan E. Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat. J. Clin. Invest. 102(2), 445-454 (1998).
16. Choe N, Tanaka S, Xia W, Hemenway DR, Roggli VL, Kagan E. Pleural macrophage recruitment and activation in asbestosinduced pleural injury. Environ. Health Perspect. 105(Suppl. 5), S1257-S1260 (1997).
17. Bograd AJ, Suzuki K, Vertes E et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol. Immunother. 60(11), 1509-1527 (2011).
18. Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J. Med. Sci. 71(1-2), 1-10 (2009).
19. Toyokuni S. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci. 100(1), 9-16 (2009).
20. Toyokuni S. Iron as a target of chemoprevention for longevity in humans. Free Radic. Res. 45(8), 906-917 (2011).
21. Barrett JC, Lamb PW, Wiseman RW. Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers. Environ. Health Perspect. 81, 81-89 (1989).
22. Davis JM. Mineral fibre carcinogenesis: experimental data relating to the importance of fibre type, size, deposition, dissolution and migration. IARC Sci. Publ. 90, 33-45 (1989).
23. Murakami H, Mizuno T, Taniguchi T et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71(3), 873-883 (2011).
24. Sekido Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol. Int. 61(6), 331-344 (2011).
25. Lang-Lazdunski L, Bille A, Lal R et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J. Thorac. Oncol. 7(4), 737-743 (2012).
26. Tokunaga T, Higashiyama M, Okami J, Maeda J, Fujiwara A, Kodama K. Intrathoracic chemo-thermotherapy with radiofrequency waves after extrapleural pneumonectomy for malignant pleural mesothelioma. Interact. Cardiovasc. Thorac. Surg. 13(3), 267-270 (2011).
27. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
28. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23(28), 6881-6889 (2005).
29. Ramos-Nino ME, Testa JR, Altomare DA et al. Cellular and molecular parameters of mesothelioma. J. Cell. Biochem. 98(4), 723-734 (2006).
30. Edwards JG, Swinson DEB, Jones JL, Waller DA, O'Byrne KJ. EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54(3), 399-407 (2006).
31. Govindan R, Kratzke RA, Herndon JE 2nd et al. Gefitinib in patients with malignant mesothelioma: A Phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 11(6), 2300-2304 (2005).
32. Garland LL, Rankin C, Gandara DR et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J. Clin. Oncol. 25(17), 2406-2413 (2007).
33. Foster JM, Radhakrishna U, Govindarajan V et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J. Surg. Oncol. 8, 88 (2010).
34. Kalra N, Ashai A, Xi L et al. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncol. Rep. 27(6), 1794-1800 (2012).
35. Baas P, Buikhuisen W, Dalesio O et al. A multicenter, randomized Phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J. Clin. Oncol. 29(Suppl.), Abstract 7006 (2011).
36. Dubey S, Jänne PA, Krug L et al. A Phase II study of sorafenib in malignant mesothelioma: Results of cancer and leukemia group B 30307. J. Thorac. Oncol. 5(10), 1655-1661 (2010).
37. Dowell JE, Kindler HL. Antiangiogenic therapies for mesothelioma. Hematol. Oncol. Clin. North Am. 19(6), 1137-1145, viii (2005).
38. Jakobsen JN, Sørensen JB. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother. Pharmacol. 68(1), 1-15 (2011).
39. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J. Thorac. Oncol. 5(2), 275-279 (2010).
40. Porta C. The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30). Future Oncol. 8(1), 13-15 (2012).
41. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma - possible immunological mechanism. Lung Cancer 32(2), 197-201 (2001).
42. Pilling JE, Nicholson AG, Harmer C, Goldstraw P. Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma. Ann. Thorac. Surg. 83(1), 314-315 (2007).
43. Allen RK. Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura. Med. J. Aust. 187(7), 413-415 (2007).
44. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S. Afr. Med. J. 61(26), 1007-1009 (1982).
45. Anraku M, Cunningham KS, Yun Z et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 135(4), 823-829 (2008).
46. Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 117(22), 5234-5244 (2011).
47. Kumagai-Takei N, Maeda M, Chen Y et al. Asbestos induces reduction of tumor immunity. Clin. Dev. Immunol. 2011, 481439 (2011).
48. Webster I, Cochrane JW, Burkhardt KR. Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S. Afr. Med. J. 61(8), 277-278 (1982).
49. Grégoire M. What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh. Migr. 4(1), 153-161 (2010).
50. Astoul P, Viallat JR, Laurent JC, Brandely M, Boutin C. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 103(1), 209-213 (1993).
51. Goey SH, Eggermont AM, Punt CJ et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: A Phase I-II study. Br. J. Cancer 72(5), 1283-1288 (1995).
52. Davidson JA, Musk AW, Wood BR et al. Intralesional cytokine therapy in cancer: A pilot study of GM-CSF infusion in mesothelioma. J. Immunother. 21(5), 389-398 (1998).
53. Boutin C, Nussbaum E, Monnet I et al. Intrapleural treatment with recombinant g-interferon in early stage malignant pleural mesothelioma. Cancer 74(9), 2460-2467 (1994).
54. O'Reilly EM, Ilson DH, Saltz LB, Heelan R, Martin L, Kelsen DP. A Phase II trial of interferon a-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest. 17(3), 195-200 (1999).
55. Sterman DH, Haas A, Moon E et al. A trial of intrapleural adenoviral-mediated interferon-a2b gene transfer for malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 184(12), 1395-1399 (2011).
56. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44(1), 46-53 (2008).
57. Hassan R, Bullock S, Premkumar A et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 13(17), 5144-5149 (2007).
58. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin. Cancer Res. 15(16), 5274-5279 (2009).
59. Hassan R, Cohen SJ, Phillips M et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin. Cancer Res. 16(24), 6132-6138 (2010).
60. Hassan R, Ebel W, Routhier EL et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumorassociated mesothelin. Cancer Immun. 7, 20 (2007).
61. Hassan R, Jahan TM, Kindler HL et al. Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter Phase II clinical trial. J. Clin. Oncol. 30(Suppl.), Abstract 7030 (2012).
62. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 5(12), 928-940 (2005).
63. Carpenito C, Milone MC, Hassan R et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106(9), 3360-3365 (2009).
64. Zhao Y, Moon E, Carpenito C et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70(22), 9053-9061 (2010).
65. Hegmans JP, Veltman JD, Lambers ME et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med. 181(12), 1383-1390 (2010).
66. Ljunggren HG. Dendritic cells, dendritic cell-based vaccines and Ralph Steinman. J. Intern. Med. 271(2), 174-176 (2012).
67. McDonnell AM, Robinson BWS, Currie AJ. Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin. Dev. Immunol. 2010, 539519 (2010).
68. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 15(1), 39-50 (2008).
69. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012).
70. Boonman ZF, van Mierlo GJ, Fransen MF et al. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J. Immunol. 172(3), 1567-1574 (2004).
71. McDonnell AM, Prosser AC, van Bruggen I, Robinson BWS, Currie AJ. CD8a+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur. J. Immunol. 40(6), 1617-1627 (2010).
72. van Mierlo GJ, Boonman ZF, Dumortier HM et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol. 173(11), 6753-6759 (2004).
73. Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J. Immunol. 181(1), 155-164 (2008).
74. Qu X, Yang MX, Kong BH et al. Hypoxia inhibits the migratory capacity of human monocyte-derived dendritic cells. Immunol. Cell. Biol. 83(6), 668-673 (2005).
75. Zhao W, Darmanin S, Fu Q et al. Hypoxia suppresses the production of matrix metalloproteinases and the migration of human monocyte-derived dendritic cells. Eur. J. Immunol. 35(12), 3468-3477 (2005).
76. Gottfried E, Kunz-Schughart LA, Ebner S et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107(5), 2013-2021 (2006).
77. Sharma S, Stolina M, Yang SC et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 9(3), 961-968 (2003).
78. Bennaceur K, Popa I, Portoukalian J, Berthier-Vergnes O, Péguet-Navarro J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int. Immunol. 18(6), 879-886 (2006).
79. Shurin MR, Shurin GV, Lokshin A et al Intratumoral cytokines/chemokines/ growth factors and tumor infiltrating dendritic cells: Friends or enemies? Cancer Metastasis Rev. 25(3), 333-356 (2006).
80. Gottfried E, Kreutz M, Haffner S et al. Differentiation of human tumour-associated dendritic cells into endothelial-like cells: An alternative pathway of tumour angiogenesis. Scand. J. Immunol. 65(4), 329-335 (2007).
81. Lu J, Liu K, Zhao J et al. VEGF-A not Ang2 mediates endothelial-like differentiation of immature DCs by ERK1/2 signaling in the microenvironment of human colon adenocarcinoma. Int. J. Oncol. 38(6), 1579-1588 (2011).
82. Ménétrier-Caux C, Bain C, Favrot MC, Duc A, Blay JY. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br. J. Cancer 79(1), 119-130 (1999).
83. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6(5), 1755-1766 (2000).
84. Coventry BJ, Lee PL, Gibbs D, Hart DN. Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br. J. Cancer 86(4), 546-551 (2002).
85. Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin. Dev. Immunol. 2011, 430394 (2011).
86. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J. 27(6), 1086-1095 (2006).
87. Ebstein F, Sapede C, Royer PJ et al. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 169(12), 1322-1330 (2004).
88. Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 171(10), 1168-1177 (2005).
89. Conejo-Garcia JR, Benencia F, Courreges MC et al. Tumor-infiltrating dendritic cell precursors recruited by a b-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10(9), 950-958 (2004).
90. Emens LA. Chemotherapy and tumor immunity: An unexpected collaboration. Front. Biosci. 13, 249-257 (2008).
91. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 52(2), 189-197 (2006).
92. Li D, Romain G, Flamar AL et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J. Exp. Med. 209(1), 109-121 (2012).
93. Grégoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 21(7-8), 791-794 (2003).
94. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61(17), 6451-6458 (2001).
95. Marroquin CE, Westwood JA, Lapointe R et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J. Immunother. 25(3), 278-288 (2002).
96. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol. Rev. 234(1), 45-54 (2010).
97. Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2(1), 37-56 (2010).
98. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Semin. Immunol. 23(1), 12-20 (2011).
99. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 211(6-8), 599-608 (2006).
100. Simon T, Tanguy-Royer S, Royer PJ et al. Human dendritic cells sequentially matured with CD4+ T cells as a secondary signal favor CTL and long-term T memory cell responses. Biol Res. 45(1), 33-43 (2012).
101. Gregoire M. Dendritic cell vaccination as a treatment modality for mesothelioma. Expert Rev. Respir. Med. 4(3), 311-314 (2010).
102. Tuyaerts S, Aerts JL, Corthals J et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56(10), 1513-1537 (2007).
103. van den Ancker W, van Luijn MM, Westers TM et al. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy 2(1), 69-83 (2010).
104. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit. Rev. Oncol. Hematol. 77(1), 12-19 (2011).
105. Vincent J, Mignot G, Chalmin F et al. 5-fluorouracil selectively kills tumorassociated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010).
106. Veltman JD, Lambers ME, van Nimwegen M et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. BMC Cancer 10(1), 464 (2010).
107. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86(5), 1065-1073 (2009).
108. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 141(1), 39-51 (2010).
109. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Invest. 122(3), 787-795 (2012).
110. Veltman JD, Lambers MEH, van Nimwegen M et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br. J. Cancer 103(5), 629-641 (2010).
111. Coward J, Kulbe H, Chakravarty P et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17(18), 6083-6096 (2011).
112. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl Med. 9(1), 216 (2011).
113. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612-1616 (2011).
114. Hume DA, MacDonald KP. Therapeutic applications of macrophage colonystimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119(8), 1810-1820 (2012).
115. Baecher-Allan CM, Hafler DA. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells. Clin. Immunol. 117(2), 192; discussion 193 (2005).
116. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28(6), 582-592 (2005).
117. Ruddle JB, Harper CA, Hönemann D, Seymour JF, Prince HM A denileukin diftitox (Ontak) associated retinopathy? Br. J. Ophthalmol. 90(8), 1070-1071 (2006).
118. Attia P, Powell DJ Jr, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J. Immunother. 29(2), 208-214 (2006).
119. Powell DJ Jr, Felipe-Silva A, Merino MJ et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 179(7), 4919-4928 (2007).
120. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007).
121. Hancock WW, Lui Y, Wang L et al. p300 targeting impairs treg function and promotes host anti-tumor immunity. 72(8 Suppl. 1), Abstract 4842 (2012).
122. Busse A, Asemissen AM, Nonnenmacher A et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur. J. Cancer 47(5), 690-696 (2011).
123. Fridlender ZG, Buchlis G, Kapoor V et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 70(1), 109-118 (2010).
124. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
125. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012). (Pubitemid 41123409)